FLUDARABINE PHARMACOKINETICS IN NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTAT

氟达拉滨在非清髓性造血细胞移植中的药代动力学

• 批准号: 7375932
• 负责人: Pamala A Jacobson
• 金额: $ 8.88万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375932
• 关键词: FLUDARABINE; PHARMACOKINETICS; NONMYELOABLATIVE; HEMATOPOIETIC; CELL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall objective of this research project is to investigate the pharmacokinetics of fludarabine in patients undergoing nonmyeloablative hematopoietic cell transplantation (HCT). Aim I will characterize pharmacokinetics of fludarabine in HCT patients at first dose and steady state. Aims II and III will investigate pharmacokinetic measures and their relationship to renal function, engraftment and neurotoxicity. Aim IV is to obtain patient DNA for pharmacokinetic studies.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究项目的总体目标是研究氟达拉滨在接受非清髓性造血细胞移植（HCT）患者中的药代动力学。目的研究氟达拉滨在HCT患者中首次给药和稳态时的药代动力学特征。目的II和III将研究药代动力学指标及其与肾功能、植入和神经毒性的关系。目的IV是获得用于药代动力学研究的患者DNA。